Clinical Trial

Safety and Modulation of Adaptive Immunity by Iscador® Qu Viscum Album Extract in Patients With Advanced, Recurrent or Metastatic Cancers Treated With Immune Checkpoint Inhibitors

Study acronym: ISCA-CHECK
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The main objective of this study is to test if adding the mistletoe extract Iscador® Qu to regular cancer treatment with immune checkpoint inhibitors affects: * The immune system's ability to fight cancer * Safety of the treatment * How well the treatment performs against cancer * How the patient feels during treatment Researchers will compare patients treated with immune checkpoint inhibitors plus Iscador® Qu with patients treated with imune checkpoint inhibitors only.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-05-07; most recent amendment 2024-12-23.
Status change: Not Yet Recruiting → Recruiting 2024-12-18
Trial Details
NCT Number NCT06408688
Lead Sponsor University Hospital, Basel, Switzerland
Conditions Advanced Solid Tumor
Enrollment 100 participants
Start Date 2024-06-24
Primary Completion 2026-11 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2024-12-27